Compare Stocks: DTIL, PHAR, FDMT, and CTMX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.65 -1.6%	$3.49	$1.90 ▼ $8.21	$795.33M	2.14	4.82 million shs	1.98 million shs
DTIL Precision BioSciences	$7.40 -0.9%	$7.87	$3.53 ▼ $9.62	$204.24M	1.24	321,248 shs	139,855 shs
FDMT 4D Molecular Therapeutics	$14.63 -2.3%	$12.57	$6.47 ▼ $16.93	$808.16M	2.74	832,148 shs	542,027 shs
PHAR Pharming Group	$11.50 +2.4%	$12.28	$9.62 ▼ $21.34	$813.97M	0.01	19,019 shs	21,512 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	0.00%	+10.42%	+7.23%	+24.50%	+62.72%
DTIL Precision BioSciences	0.00%	-2.23%	-0.27%	+8.89%	+47.34%
FDMT 4D Molecular Therapeutics	0.00%	+6.09%	+39.26%	+62.19%	+105.91%
PHAR Pharming Group	0.00%	-2.18%	+3.50%	-10.80%	-25.78%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.65 -1.6%	$3.49	$1.90 ▼ $8.21	$795.33M	2.14	4.82 million shs	1.98 million shs
DTIL Precision BioSciences	$7.40 -0.9%	$7.87	$3.53 ▼ $9.62	$204.24M	1.24	321,248 shs	139,855 shs
FDMT 4D Molecular Therapeutics	$14.63 -2.3%	$12.57	$6.47 ▼ $16.93	$808.16M	2.74	832,148 shs	542,027 shs
PHAR Pharming Group	$11.50 +2.4%	$12.28	$9.62 ▼ $21.34	$813.97M	0.01	19,019 shs	21,512 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	0.00%	+10.42%	+7.23%	+24.50%	+62.72%
DTIL Precision BioSciences	0.00%	-2.23%	-0.27%	+8.89%	+47.34%
FDMT 4D Molecular Therapeutics	0.00%	+6.09%	+39.26%	+62.19%	+105.91%
PHAR Pharming Group	0.00%	-2.18%	+3.50%	-10.80%	-25.78%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	226.03% Upside
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	335.81% Upside
FDMT 4D Molecular Therapeutics	2.80	Moderate Buy	$29.63	102.49% Upside
PHAR Pharming Group	2.20	Hold	$38.67	236.23% Upside

Current Analyst Ratings Breakdown

Latest DTIL, PHAR, FDMT, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$32.00
8/13/2026	CTMX CytomX Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $11.00
8/10/2026	CTMX CytomX Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$15.00 ➝ $14.00
8/7/2026	PHAR Pharming Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/5/2026	DTIL Precision BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
7/31/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$37.00
7/31/2026	PHAR Pharming Group	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$18.30M	43.45	N/A	N/A	$0.58 per share	6.29
DTIL Precision BioSciences	$34.26M	5.96	N/A	N/A	$4.03 per share	1.84
FDMT 4D Molecular Therapeutics	$85.21M	9.48	N/A	N/A	$8.85 per share	1.65
PHAR Pharming Group	$376.13M	2.16	$0.21 per share	55.99	$3.95 per share	2.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
DTIL Precision BioSciences	-$45.72M	-$2.80	N/A	N/A	N/A	-96.73%	-72.52%	-32.25%	11/2/2026 (Estimated)
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.63	N/A	N/A	N/A	-194.74%	-41.33%	-35.90%	11/10/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	95.83	38.33	N/A	2.51%	3.40%	1.90%	11/5/2026 (Estimated)

Latest DTIL, PHAR, FDMT, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	-$1.04	-$0.02	-$1.04	$3.62 million	$3.78 million
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million
8/6/2026	Q2 2026	DTIL Precision BioSciences	-$0.8040	-$1.26	-$0.4560	-$1.26	$0.74 million	N/A
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	9.36	9.36
DTIL Precision BioSciences	0.50	12.82	12.82
FDMT 4D Molecular Therapeutics	0.05	8.03	8.03
PHAR Pharming Group	0.34	3.01	2.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
DTIL Precision BioSciences	37.99%
FDMT 4D Molecular Therapeutics	99.27%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	3.80%
DTIL Precision BioSciences	2.70%
FDMT 4D Molecular Therapeutics	7.90%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	217.90 million	209.62 million	Optionable
DTIL Precision BioSciences	200	27.60 million	26.86 million	No Data
FDMT 4D Molecular Therapeutics	120	55.24 million	50.88 million	Optionable
PHAR Pharming Group	280	70.78 million	69.31 million	Not Optionable

DTIL, PHAR, FDMT, and CTMX Headlines

Recent News About These Companies

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Consensus Rating of "Hold" by Analysts

September 7 at 4:15 AM | americanbankingnews.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Consensus Recommendation of "Hold" by Brokerages

September 7 at 4:13 AM | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - Should You Buy?

September 2, 2026 | marketbeat.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Increase in Short Interest

August 27, 2026 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - What's Next?

August 26, 2026 | marketbeat.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 93.0% in July

August 16, 2026 | marketbeat.com

Pharming introduces Joenja in Japan for adult and paediatric patients with activated PI3K delta syndrome aged 4 and older

August 14, 2026 | pharmabiz.comP

Pharming Group N.V.: Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older

August 13, 2026 | finanznachrichten.de

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Brokerages

August 13, 2026 | marketbeat.com

Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older

August 13, 2026 | markets.businessinsider.com

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?

August 12, 2026 | marketbeat.com

Pharming Group (PHAR) Stock Price, Quote, News & History

August 12, 2026 | benzinga.com

Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume - Time to Buy?

August 11, 2026 | marketbeat.com

Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky

August 7, 2026 | prnewswire.com

Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 5, 2026 | tmcnet.com

Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.

August 5, 2026 | businesswire.com

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Pharming Group (PHAR)

August 5, 2026 | globenewswire.com

PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)

August 4, 2026 | tmcnet.com

Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference

August 4, 2026 | finance.yahoo.com

Pharming Group Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Pharming Group (PHAR)

July 31, 2026 | prnewswire.com

Pharming Group N.V. (PHAR) Q2 2026 Earnings Call Transcript

July 30, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DTIL, PHAR, FDMT, and CTMX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$3.65 -0.06 (-1.62%)

Closing price 04:00 PM Eastern

Extended Trading

$3.67 +0.02 (+0.52%)

As of 06:56 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Precision BioSciences NASDAQ:DTIL

$7.40 -0.07 (-0.94%)

Closing price 04:00 PM Eastern

Extended Trading

$7.40 -0.01 (-0.07%)

As of 06:32 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

4D Molecular Therapeutics NASDAQ:FDMT

$14.63 -0.34 (-2.27%)

Closing price 04:00 PM Eastern

Extended Trading

$14.63 0.00 (0.00%)

As of 06:07 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Pharming Group NASDAQ:PHAR

$11.50 +0.27 (+2.40%)

Closing price 04:00 PM Eastern

Extended Trading

$11.50 -0.01 (-0.04%)

As of 04:24 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DTIL, PHAR, FDMT, and CTMX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DTIL, PHAR, FDMT, and CTMX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DTIL, PHAR, FDMT, and CTMX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DTIL, PHAR, FDMT, and CTMX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Precision BioSciences NASDAQ:DTIL

4D Molecular Therapeutics NASDAQ:FDMT

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DTIL, PHAR, FDMT, and CTMX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DTIL, PHAR, FDMT, and CTMX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DTIL, PHAR, FDMT, and CTMX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DTIL, PHAR, FDMT, and CTMX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Precision BioSciences NASDAQ:DTIL

4D Molecular Therapeutics NASDAQ:FDMT

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools